Eli Lilly Signs Up-to-$5.9B Oncology Pact With Stipple Bio and Agrees to Buy Calytrix Bio for Up to $1.5B

SentiSense · Published · Updated

Eli Lilly struck two oncology deals on November 16: a research collaboration and license agreement with Stipple Bio carrying up to $5.9 billion in milestone payments plus royalties, and an agreement to acquire Calytrix Bio, a preclinical blood-cancer startup, for up to $1.5 billion in cash. Neither company disclosed the upfront payments, so most of the headline value is contingent on research, clinical and regulatory milestones.

LLY announced two oncology transactions on November 16. Stipple Bio said it entered a multi-target, multi-modality research collaboration and license agreement with Lilly under which it receives an upfront payment, an equity investment, and up to $5.9 billion in research, development and commercialization milestones, plus tiered royalties on any products Lilly commercializes. Separately, Lilly agreed to acquire privately held Calytrix Bio, with Calytrix shareholders eligible for up to $1.5 billion in cash, inclusive of an upfront payment and milestone payments.

The two deals target different corners of cancer care. Stipple's platform identifies tumor-specific cell surface binders, and Lilly gets exclusive worldwide rights to products from the collaboration; Stipple plans to start a Phase 1 trial of its first antibody-drug conjugate, STP-100, in solid tumors in early 2027. Calytrix, founded in 2025, is developing a preclinical biparatopic antibody against mutant calreticulin for the rare blood cancers essential thrombocythemia and myelofibrosis, which would sit alongside Lilly's existing hematology drug Jaypirca.

The headline figures are ceilings rather than committed cash: neither Stipple nor Calytrix disclosed upfront amounts, and Calytrix did not give a closing date. The deals also rippled into small-cap oncology names. SLS (SELLAS Life Sciences) rose as much as 12% in extended trading as retail traders compared the up-to-$1.5 billion Calytrix price with SELLAS's roughly $1.52 billion market value, though SELLAS has no relationship to either transaction.

What to watch: whether Lilly discloses the upfront payments in its next quarterly filing, the start of the STP-100 Phase 1 trial in early 2027, and Calytrix's path into the clinic. Both deals extend Lilly's push beyond diabetes and obesity into oncology through early-stage assets, where most of the value depends on clinical outcomes years away.

Related Stocks

Powered by SentiSense - Intelligent Market Analysis